United Therapeutics Corporation Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax
United Therapeutics Corporation (UTHR) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax of $200.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax · last filed 2026-02-25
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2025 was $200.00K, a 50.00% decline from fiscal 2024.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2024 was $400.00K, a 20.00% decline from fiscal 2023.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2023 was $500.00K.
- United Therapeutics Corporation other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2022 was -$1.10M.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax 12 month |
|---|---|
| 2025-12-31 | $200.00K 10-K · filed 2026-02-25 |
| 2024-12-31 | $400.00K 10-K · filed 2026-02-25 |
| 2023-12-31 | $500.00K 10-K · filed 2026-02-25 |
| 2022-12-31 | -$1.10M 10-K · filed 2025-02-26 |
| 2021-12-31 | -$300.00K 10-K · filed 2024-02-21 |
| 2020-12-31 | $400.00K 10-K · filed 2023-02-22 |
| 2019-12-31 | $1.00M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |